Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%24/7 Wall Street • 09/24/26
Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior NotesPRNewsWire • 09/24/26
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should KnowZacks Investment Research • 09/23/26
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior NotesPRNewsWire • 09/23/26
Viking Therapeutics: 'Strong Buy' On Injectable VK2735 Maintenance Data And Treatment OptionalitySeeking Alpha • 09/23/26
Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%24/7 Wall Street • 09/23/26
Viking Therapeutics, Inc. (VKTX) Discusses Top Line Data from VK2735 Maintenance Study in Obesity and Type 2 Diabetes TranscriptSeeking Alpha • 09/22/26
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a monthMarket Watch • 09/22/26
Viking Therapeutics shares surge over 27% on weight loss drug maintenance dataProactive Investors • 09/22/26
Viking Therapeutics' VK2735 Shows Strong Weight-Loss Retention With Monthly DosingMarketBeat • 09/22/26
Weight Loss Drug: Viking Therapeutics Says Lead Obesity Drug Shows Weight Retention with Less Frequent DosingBenzinga • 09/22/26
Viking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo's Obesity Empire.Barrons • 09/22/26
Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.Investors Business Daily • 09/22/26
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing RegimensPRNewsWire • 09/22/26
Novo Nordisk Falls 7% as Post-Wegovy Growth Plan Fails to Ease Competition Fears; Eli Lilly Slips, Viking Therapeutics Edges Higher24/7 Wall Street • 09/21/26